Repurposing antihypertensive drugs for the prevention of Alzheimer's disease: a Mendelian randomization study

被引:56
作者
Walker, Venexia M. [1 ,2 ]
Kehoe, Patrick G. [3 ,4 ]
Martin, Richard M. [1 ,2 ]
Davies, Neil M. [1 ,2 ]
机构
[1] Univ Bristol, Med Res Council Integrat Epidemiol Unit, Bristol, Avon, England
[2] Univ Bristol, Bristol Med Sch Populat Hlth Sci, Bristol, Avon, England
[3] Univ Bristol, Dementia Res Grp, Bristol, Avon, England
[4] Univ Bristol, Bristol Med Sch Translat Hlth Sci, Bristol, Avon, England
基金
英国医学研究理事会;
关键词
Mendelian randomization; drug repurposing; Alzheimer's disease; hypertension; antihypertensive drugs; BLOOD-PRESSURE; INSTRUMENTS; RISK;
D O I
10.1093/ije/dyz155
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background: Evidence concerning the potential repurposing of antihypertensives for Alzheimer's disease prevention is inconclusive. We used Mendelian randomization, which can be more robust to confounding by indication and patient characteristics, to investigate the effects of lowering systolic blood pressure, via the protein targets of different antihypertensive drug classes, on Alzheimer's disease. Methods: We used summary statistics from genome-wide association studies of systolic blood pressure and Alzheimer's disease in a two-sample Mendelian randomization analysis. We identified single-nucleotide polymorphisms (SNPs) that mimic the action of antihypertensive protein targets and estimated the effect of lowering systolic blood pressure on Alzheimer's disease in three ways: (i) combining the protein targets of antihypertensive drug classes, (ii) combining all protein targets and (iii) without consideration of the protein targets. Results: There was limited evidence that lowering systolic blood pressure, via the protein targets of antihypertensive drug classes, affected Alzheimer's disease risk. For example, the protein targets of calcium channel blockers had an odds ratio (OR) per 10 mmHg lower systolic blood pressure of 1.53 [95% confidence interval (CI): 0.94 to 2.49; p= 0.09; SNPs = 17]. We also found limited evidence for an effect when combining all protein targets (OR per 10 mmHg lower systolic blood pressure: 1.14; 95% CI: 0.83 to 1.56; p= 0.41; SNPs = 59) and without consideration of the protein targets (OR per 10 mmHg lower systolic blood pressure: 1.04; 95% CI: 0.95 to 1.13; p= 0.45; SNPs = 153). Conclusions: Mendelian randomization suggests that lowering systolic blood pressure via the protein targets of antihypertensive drugs is unlikely to affect the risk of developing Alzheimer's disease. Consequently, if specific antihypertensive drug classes do affect the risk of Alzheimer's disease, they may not do so via systolic blood pressure.
引用
收藏
页码:1132 / 1140
页数:9
相关论文
共 37 条
  • [21] Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials
    Law, MR
    Wald, NJ
    Morris, JK
    Jordan, RE
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2003, 326 (7404): : 1427 - 1431
  • [22] Nilvadipine in mild to moderate Alzheimer disease: A randomised controlled trial
    Lawlor, Brian
    Segurado, Ricardo
    Kennelly, Sean
    Rikkert, Marcel G. M. Olde
    Howard, Robert
    Pasquier, Florence
    Borjesson-Hanson, Anne
    Tsolaki, Magda
    Lucca, Ugo
    Molloyid, D. William
    Coen, Robert
    Riepe, Matthias W.
    Kalman, Janos
    Kenny, Rose Anne
    Cregg, Fiona
    O'Dwyer, Sarah
    Walsh, Cathal
    Adams, Jessica
    Banzi, Rita
    Breuilh, Laetitia
    Daly, Leslie
    Hendrix, Suzanne
    Aisen, Paul
    Gaynor, Siobhan
    Sheikhi, Ali
    Taekema, Diana G.
    Verhey, Frans R.
    Nemni, Raffaello
    Nobili, Flavio
    Franceschi, Massimo
    Frisoni, Giovanni
    Zanetti, Orazio
    Konsta, Anastasia
    Anastasios, Orologas
    Nenopoulou, Styliani
    Tsolaki-Tagaraki, Fani
    Pakaski, Magdolna
    Dereeper, Olivier
    de la Sayette, Vincent
    Senechal, Olivier
    Lavenu, Isabelle
    Devendeville, Agnes
    Calais, Gauthier
    Crawford, Fiona
    Mullan, Michael
    [J]. PLOS MEDICINE, 2018, 15 (09):
  • [23] Mendelian randomization: Using genes as instruments for making causal inferences in epidemiology
    Lawlor, Debbie A.
    Harbord, Roger M.
    Sterne, Jonathan A. C.
    Timpson, Nic
    Smith, George Davey
    [J]. STATISTICS IN MEDICINE, 2008, 27 (08) : 1133 - 1163
  • [24] Triangulation in aetiological epidemiology
    Lawlor, Debbie A.
    Tilling, Kate
    Smith, George Davey
    [J]. INTERNATIONAL JOURNAL OF EPIDEMIOLOGY, 2016, 45 (06) : 1866 - 1886
  • [25] Commentary: Two-sample Mendelian randomization: opportunities and challenges
    Lawlor, Debbie A.
    [J]. INTERNATIONAL JOURNAL OF EPIDEMIOLOGY, 2016, 45 (03) : 908 - 915
  • [26] Genetically Determined Fibrinogen, Gamma Prime Fibrinogen and Risk of Venous Thromboembolism and Ischemic Stroke: Evidence From Mendelian Randomization
    Maners, Jillian
    Gill, Dipender
    Pankratz, Nathan
    Tang, Weihong
    Smith, Nicholas L.
    Morrison, Alanna C.
    Dehghan, Abbas
    de Vries, Paul S.
    [J]. CIRCULATION, 2019, 139
  • [27] Associations between Potentially Modifiable Risk Factors and Alzheimer Disease: A Mendelian Randomization Study
    Ostergaard, Soren D.
    Mukherjee, Shubhabrata
    Sharp, Stephen J.
    Proitsi, Petroula
    Lotta, Luca A.
    Day, Felix
    Perry, John R. B.
    Boehme, Kevin L.
    Walter, Stefan
    Kauwe, John S.
    Gibbons, Laura E.
    Larson, Eric B.
    Powell, John F.
    Langenberg, Claudia
    Crane, Paul K.
    Wareham, Nicholas J.
    Scott, Robert A.
    [J]. PLOS MEDICINE, 2015, 12 (06)
  • [28] Pournelle G. H., 1953, Journal of Mammalogy, V34, P133
  • [29] Reasons that prevent the inclusion of Alzheimer's disease patients in clinical trials
    Rollin-Sillaire, Adeline
    Breuilh, Laetitia
    Salleron, Julia
    Bombois, Stephanie
    Cassagnaud, Pascaline
    Deramecourt, Vincent
    Mackowiak, Marie-Anne
    Pasquier, Florence
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2013, 75 (04) : 1089 - 1097
  • [30] Schneider LS, 2010, J NUTR HEALTH AGING, V14, P295